Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
ALL MEDICAL CODES IN CATEGORY G9013-G9140

2025 HCPCS code G9080

Oncology - Other

2025 HCPCS code G9073

Invasive female breast cancer, predominantly adenocarcinoma, Stage IIIA-IIIB (not T3, N1, M0), ER/PR positive, no progression/recurrence/metastasis, not ductal carcinoma in situ.

2025 HCPCS code G9104

Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or not listed.

2025 HCPCS code G9126

Chronic Myelogenous Leukemia, positive for Philadelphia chromosome or BCR/ABL gene, in remission.

2025 HCPCS code G9098

Cancer of the esophagus, adenocarcinoma or squamous cell carcinoma, metastatic, recurrent, or progressive disease status.

2025 HCPCS code G9074

Oncology - other. This code is used for reporting the disease status of invasive female breast cancer within a Medicare-approved demonstration project, specifically for cases where the cancer is predominantly adenocarcinoma, Stage IIIA to IIIB, not T3, N1, or M0, and is estrogen and progesterone receptor-negative (ER/PR-), excluding ductal carcinoma.

2025 HCPCS code G9089

Oncology - disease status; colon cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; extent of disease unknown, staging in progress, or extent not listed in patient record.

2025 HCPCS code G9059

Indicates that a cancer patient's management differs from practice guidelines due to their choice of alternative treatment or no treatment after guideline-consistent treatment was offered.

2025 HCPCS code G9113

Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 1) without recurrence or progression.

2025 HCPCS code G9105

Oncology; disease status; pancreatic cancer, limited to adenocarcinoma as predominant cell type; post r0 resection without evidence of disease progression, recurrence, or metastases.

2025 HCPCS code G9137

Oncology; disease status; Non-Hodgkin’s lymphoma, any cellular classification; relapsed/refractory (for use in a Medicare-approved demonstration project).

2025 HCPCS code G9136

Disease status of non-Hodgkin’s lymphoma with transformation of cell type from one classification to another (Used in a Medicare demonstration project in 2006).

2025 HCPCS code G9102

Oncology; disease status; gastric cancer, limited to adenocarcinoma, clinical or pathologic M0, unresectable with no evidence of disease progression (for use in a Medicare-approved demonstration project).

2025 HCPCS code G9061

Available practice guidelines do not address the patient's specific cancer condition.

2025 HCPCS code G9054

Supervising, coordinating, or managing care of a patient with terminal cancer or for whom other medical illness prevents further cancer treatment.

2025 HCPCS code G9107

Oncology - other

2025 HCPCS code G9109

Disease status of head and neck cancer, limited to cancers of the oral cavity, pharynx, and larynx with squamous cell as the predominant cell type, showing no disease progression.

2025 HCPCS code G9134

Non-Hodgkin’s lymphoma, stage I/II, any cell type, not relapsed/recurrent, nonrefractory.

2025 HCPCS code G9130

Oncology - Other

2025 HCPCS code G9129

Oncology - Other (Medicare demonstration project, 2006)

2025 HCPCS code G9128

Multiple Myeloma, Stage IA

2025 HCPCS code G9079

Oncology - Prostate cancer, limited to adenocarcinoma, T3B to T4, any N, any T, at initial diagnosis was N1, no evidence of disease progression, recurrence, or metastasis, for Medicare demonstration project.

2025 HCPCS code G9108

Provides information on the disease status of metastatic pancreatic adenocarcinoma with unknown extent of progression; used in a 2006 Medicare demonstration project.

2025 HCPCS code G9056

This HCPCS code reports adherence to practice guidelines for oncology treatment within a specific Medicare demonstration project.

2025 HCPCS code G9132

Oncology - Other

2025 HCPCS code G9135

Oncology; Disease status; Non-Hodgkin’s lymphoma, any cellular classification; Stage III, IV, not relapsed, not refractory.

2025 HCPCS code G9069

Oncology - disease status; small cell lung cancer (limited to small cell and combined small cell/non-small cell); extensive stage at diagnosis, metastatic, locally recurrent, or progressive. For use in a Medicare-approved demonstration project.

2025 HCPCS code G9068

Oncology disease status limited to small cell and combined small cell/non-small cell; extent of disease initially established as limited with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project).

2025 HCPCS code G9094

Oncology; disease status; rectal cancer, limited to invasive cancer, adenocarcinoma as predominant cell type; m1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project).

2025 HCPCS code G9014

ESRD demo expanded bundle including venous access and related services.

2025 HCPCS code G9060

Oncology - Management Differs From Practice Guidelines.

2025 HCPCS code G9016

Smoking cessation counseling, individual, per session (6-10 minutes), used in Medicare demonstration projects.

2025 HCPCS code G9071

Oncology - Current Disease Status, Invasive Female Breast Cancer, Adenocarcinoma as Predominant or Main Cell Type, Stage I or IIA to IIB, or T3, N1, M0 Category, ER and/or PR Positive Type, Not Ductal Carcinoma, No Evidence of Disease Progression, Recurrence, or Metastasis

2025 HCPCS code G9095

Oncology – other. This code reports a patient's disease status for a Medicare demonstration project when the patient has rectal cancer that is predominantly adenocarcinoma, and the extent is unknown, staging is in progress, or the extent is not listed.

2025 HCPCS code G9131

Oncology - Other

2025 HCPCS code G9103

Oncology; disease status; gastric cancer, limited to adenocarcinoma as predominant cell type; clinical or pathologic M1 at diagnosis, metastatic, locally recurrent, or progressive (for use in a Medicare-approved demonstration project).

2025 HCPCS code G9111

Oncology; disease status; head and neck cancer (oral cavity, pharynx, larynx with squamous cell predominance); M1 at diagnosis, metastatic, recurrent, or progressive.